Peripheral level of CD33 and Alzheimer’s disease: a bidirectional two-sample Mendelian randomization study

• DOI: 10.1038/s41398-022-02205-4
• Publication Date: 2022-10-03T13:03:00Z
• Authors: Xiaojing Gu; Meng Dou; Bei Cao; Zheng Jiang; Yongping Chen
• Keywords: Mendelian Randomization; Genome-wide Association Study

Abstract Increased expression of CD33 in the brain has been suggested to be associated with increased amyloid plaque burden, while peripheral level Alzheimer’s disease (AD) patients and its role AD remain unclear. The current study aimed systematically explore bidirectional relationship between AD. Genome-wide association (GWAS) datasets (N cases : 21982; N controls 41944), blood mRNA level, plasma protein on immune-cell subtypes were obtained from GWASs conducted European population. Eligible IVs extracted GWASs. MR estimates calculated by inverse-variance weighting (IVW) other sensitivity analyses. main statistical analyses using TwoSampleMR (v.0.5.5) R package (V.4.1.2).In forward analysis (CD33 as exposure outcome), IVW results indicated that elevated (OR [95% CI] = 1.156[1.080, 1.238], p 3.25e-05), serum 1.08 [1.031, 1.139], 1.6e-03) CD33's immune cell ( < 0.05) all leading a higher risk And supported these findings. While reverse (AD outcome) was not elevation > 0.05). In conclusion, our causal development Future studies are needed work developing biomarker therapeutic target